Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Development of resistance to therapy continues to be a serious clinical problem in lung cancer management. We previously identified that Annexin A2 is significantly up-regulated in cisplatin-resistant non-small cell lung cancer (NSCLC) A549/DDP cells. However, the exact function and molecular mechanism of Annexin A2 in cisplatin resistance of NSCLCs has not been determined. METHODS: Western blot and qRT-PCR were performed to analyze the protein and mRNA level of indicated molecules, respectively. Immunohistochemistry was performed to analyze the expression of Annexin A2 in NSCLC tissue samples. MTS assay, Colony formation assays, AnnexinV/PI apoptosis assay, Luciferase Reporter Assay, Chromatin-immunoprecipitation, and nude mice xenograft assay were used to visualize the function of Annexin A2 on cisplatin resistance. RESULTS: Our results demonstrated that knockdown of Annexin A2 increased cisplatin sensitivity of cisplatin-resistant A549/DDP cells both in vitro and in vivo, whereas overexpression of Annexin A2 increased cisplatin resistance of A549, H460 and H1650 cells. Moreover, we found that Annexin A2 enhanced cisplatin resistance via inhibition of cisplatin-induced cell apoptosis. Our studies showed that Annexin A2 suppressed the expression of p53 through activation of JNK/c-Jun signaling, which in turn resulted in a decrease in the expression of p53-regulated apoptotic genes p21, GADD45 and BAX, as well as p53-dependent cell apoptosis. Furthermore, we found that in NSCLC cases that Annexin A2 is highly expressed; it is positively correlated with a poor prognosis, as well as correlated with short disease-free survival for patients who received chemotherapy after surgery. CONCLUSIONS: These data suggested that Annexin A2 induces cisplatin resistance of NSCLCs via regulation of JNK/c-Jun/p53 signaling, and provided an evidence that blockade of Annexin A2 could serve as a novel therapeutic approach for overcoming drug resistance in NSCLCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“MAPK pathway activation is a common event in tumorigenesis, and plays a key role in cancer progression and invasion by regulating cell migration, proteinase induction, and apoptosis [46, 47].”
Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
Leppä, S., & Bohmann, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203173 · Cited by 522 · cited 1×
“Although JNK activation can be a positive step in the events leading a cell towards apoptosis, there are also many reports stating the opposite that activation of JNK can inhibit apoptosis and promote proliferation [49].”
c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity
Stepniak, E., Ricci, R., Eferl, R., Sumara, G., Sumara, I., Rath, M., Hui, L., & Wagner, E. F. (2006) · Genes & Development · doi:10.1101/gad.390506 · Cited by 232 · cited 1×
“repressor that negatively regulates p53 mRNA expression through bind and represses the p53 promoter [29, 30].”
Cited by
Understanding MAPK Signaling Pathways in Apoptosis
Yue, J., & López, J. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072346 · Cited by 1,245
“Besides, the JNK/c-Jun signaling pathway promotes annexin A2 overexpression that would suppress the expression of p53, and thus would decrease p53-regulated apoptotic genes [54].”
BackgroundTargeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
JNK signaling in cancer cell survival
Wu, Q., Wu, W., Fu, B., Shi, L., Wang, X., & Kuca, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21574 · Cited by 322
“The potential mechanisms are not fully explored, but some mediators, including annexin A2 and prothymosin‐alpha (PTMA), are supposed to be involved in this context.(80,85) For example, annexin A2 can enhance the cisplatin resistance through activation of JNK‐p53 signaling and decreases NSCLC cell apoptosis.”
BackgroundInfluentialStreptococcus anginosus promotes gastric inflammation, atrophy, and tumorigenesis in mice
Fu, K., Cheung, A. H. K., Wong, C. C., Liu, W., Zhou, Y., Wang, F., Huang, P., Yuan, K., Coker, O. O., Pan, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.004 · Cited by 273
Metadata
- Authors
- Feng, X., Liu, H., Zhang, Z., Gu, Y., Qiu, H., & He, Z.
- Venue
- Journal of Experimental & Clinical Cancer Research
- Published
- 2017-09-08
- Volume
- 36
- Issue
- 1
- Pages
- 123-123
- ISSN
- 0392-9078 (ISSN-L)
- 1756-9966
- OpenAlex
- W2751602291
- Cited by
- 99
- References
- 5
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. https://app.cochat.ai/papers/10.1186/s13046-017-0594-1
- The paper
- Feng, X., Liu, H., Zhang, Z., Gu, Y., Qiu, H., & He, Z. (2017). Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-017-0594-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.